Anthony J Scott, MD, PhD
1500 E Medical Ctr Dr
Ann Arbor, MI 48109
Manage Your Profile
About
My clinical interests revolve around the provision of clinical genetics care to the adult population. This includes clinical time spent between Adult Medical Genetics and Cancer Genetics. I initiated a clinical cancer genetics program at the VA Ann Arbor Healthcare System, where I have a partial clinical appointment. I am especially interested in providing cancer genetic counseling services to the Veteran community and performing cancer surveillance of individuals with hereditary cancer syndromes. Additionally, I am coordinating the return of over 2,000 clinically actionable results identified as part of the Michigan Genomics Initiative.
Qualifications
-
Medical Genetics FellowshipUniversity of Michigan Medical School, Ann Arbor, United States
2019 - 2021
Clinical Fellowship
-
Internal Medicine ResidencyUniversity of Michigan Medical School, Ann Arbor, United States
2016 - 2019
Residency
-
MD, PhDCase Western Reserve University, Cleveland, United States
2008 - 2016
-
BSUniversity of Rochester, Rochester, United States
2004 - 2008
Center Memberships
-
Center MemberAI and Digital Health Innovation
-
Center MemberRogel Cancer Center
Research Overview
My main research interest deals with improving clinical variant interpretation via a high-throughput method called deep mutational scanning to interrogate thousands of variants simultaneously. Primarily, this involves the use of a cellular model to identify pathogenic variants in Lynch Syndrome, a hereditary cancer syndrome, to help reclassify variants of uncertain significance recovered from clinical genetics testing. I am also applying these methods to an endometrial cancer model to determine how different mutations can affect tumor development and/or treatment efficacy. Moreover, I am participating in research collaborations with Ambry Genetics to identify novel variants associated with Peutz-Jeghers and Juvenile Polyposis Syndromes, as well as with Karmanos Cancer Institute to improve variant classification in African-American cancer patients.
Recent Publications
-
Vishnopolska SA, Marsh APL, Hernandez F, Jia X, Hemker S, Glick E, Glaser V, Scott A, Kitzman J. 2025 Oct 14;Proceeding / Abstract / PosterA comprehensive, clinically calibrated MAVE (multiplex assay of variant effect) for the human MutLɑ complex genes MLH1 and PMS2
-
Scott A, Hernandez F, Marsh APL, Kohler K, Jia X, Vishnopolska S, Belhadj S, Varga M, Clark G, Jayakody S, Burugula B, Karam R. 2025 Oct 14;Proceeding / Abstract / PosterA multiplex assay of variant effect (MAVE) of MSH6 enables accurate, prospective Lynch Syndrome clinical variant interpretation
-
Kitzman J, Vishnopolska S, Hemker S, Jia X, Glick E, Scott A. 2025 Sep 8;Proceeding / Abstract / PosterSystematic resolution of clinical variants in hereditary cancer syndromes using pathway-scale functional assays
-
Jiang CY, Zhao L, Green MD, Ravishankar S, Towlerton AMH, Scott AJ, Raghavan M, Cusick MF, Warren EH, Ramnath N. Scientific Reports, 2024 Dec 1; 14 (1):Journal ArticleClass II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer
DOI:10.1038/s41598-023-48546-y PMID: 38172168 -
Vanderwerff B, Fritsche L, Scott A, Bertucci-Richter E, Patil S, Boehnke M, Zhou X, Zoellner S. 2024 Nov 6;Proceeding / Abstract / PosterA custom array for genotyping rare predicted loss-of-function variants in the Michigan Genomics Initiative biobank
-
Vanderwerff B, Fritsche L, Scott A, Bertucci-Richter E, Patil S, Boehnke M, Zhou X, Zoellner S. 2024 Nov 6;Proceeding / Abstract / PosterA custom array for genotyping rare predicted loss-of-function variants in the Michigan Genomics Initiative biobank
-
Jacobs MF, Scott AJ, Spranger EK. 2024 Jun 19;Proceeding / Abstract / PosterA quality improvement initiative to leverage tumor sequencing results of gastrointestinal cancers for potential germline referrals
-
Scott A, Hernandez F, Marsh A, Jayakody S, Burugula B, Karam R. 2024 Jun 19;Proceeding / Abstract / PosterEstablishing a deep mutational scan for MSH6 missense variant classification